Recro, a CDMO providing services for complex formulation and manufacturing challenges for oral solid dose drug products, has signed a new development agreement with Astex Pharmaceuticals, Inc.   “We are excited to add Astex, a leading developer of novel therapeutics for cancer, to our growing list of CDMO customers,” said Bill Hirschman, vice president of sales and marketing for Recro. “The support we have been engaged to provide represents the type of durable, trusted relationship we work eve...